UBX — Unity Biotechnology Balance Sheet
0.000.00%
Last trade - 00:00
- $25.18m
- -$18.02m
- 22
- 35
- 20
- 15
2019 December 31st | 2020 December 31st | 2021 December 31st | C2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 127 | 97.7 | 88.1 | 94.8 | 43.2 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 129 | 101 | 90.5 | 96.5 | 46.6 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 16.6 | 36.1 | 31.2 | 26.9 | 18.1 |
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 151 | 156 | 125 | 124 | 65.7 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 17.2 | 14.5 | 16.6 | 19.6 | 7.84 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 30.5 | 73.4 | 65.1 | 68.3 | 37.3 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 121 | 82.9 | 59.6 | 56.1 | 28.4 |
Total Liabilities & Shareholders' Equity | 151 | 156 | 125 | 124 | 65.7 |
Total Common Shares Outstanding |